Airway Response to a Bronchodilator in Healthy Parents of Infants With Bronchiolitis: Results
Main characteristics of the investigated subjects are reported in Table 1. There was no significant difference for anthropometric parameters nor for smoking habit between the two groups.
As stated in the Materials and Methods section, both groups had normal mean values of baseline lung function values: control subjects had slightly higher figures than parents of infants with bronchiolitis, but not significantly higher values.
Furthermore, no significant increase in FVC, FEVp and FEF25-75% values was observed after placebo administration in group 1. Conversely, after the inhalation of salbutamol, all parameters showed an increase, expressed as percentage of variation from the baseline value. In addition, the changes of FEVj and FEF25-75% values, but not of FVC, after salbutamol administration in the parents of infants with bronchiolitis were significantly different from the values measured after placebo inhalation (Table 2). On the contrary, in the control subjects, no significant increase was observed in the spirometric parameters after salbutamol administration with respect to baseline values (Table 2). canadian neighborhood pharmacy
Finally, the changes in FVC, FEVj, and FEF25-75% values in the parents of infants with bronchiolitis were significantly different from those of the control subjects after salbutamol administration (Table 2).
Indeed, using the criteria mentioned previously, 16 (24.2 percent) subjects of group 1 had a significant increase in at least one of the measurements (FVC, FEV., and FEF25-75% [Table 3]); conversely, no change resulted in the values for the control group.
Table 1 — Characteristics of Study Groups
|Clinical Data||Parents of Bronchiolitic Infants||ControlSubjects|
|Age, yr||30.9 ±5.9||30.4 ±3.9|
|Height, cm||167.1 ±8.6||169.5 ±10.3|
|Family history of atopy||4||5|
|Baseline lung funtion parameters|
|FVC (% predicted)||101.1 ± 14.8||107.6 ±15.2|
|FEV, (% predicted)||102.1 ± 13.5||105.8 ±11.6|
|FEF25-75% (% predicted)||108.8 ± 28.4||118.1 ±31.8|
Table 2 —Mean Changes m Spirometric Indexes After Salbutamol or Placebo Inhalation (m Percent of Baseline)
|FVCFEV,FEF25-75%||1.5 ± 6.3 1.0 ±5.1 -0.6 ±11.4||2.3 ± 4.95.4 ± 6.0 15.7 ±16.6||NS0.0010.001|
|Croup 1||Croup 2|
|FVCFEV,FEF25-75%||2.3 ± 4.95.4 ± 6.0 15.7 ±16.6||-0.9 ±5.5 1.0 ±5.3 6.8 ±10.2||0.010.0020.02|
Table 3 — Number (Percent) of Subjects With a Significant Response to Salbutamol
|Criteria||Croup 1||Croup 2|
|FVC >15%||3 (4.5%)||0|
|FEV, >12%||14 (21.2%)||0|
|FEF25-75% >45%||5 (7.6%)||0|
|At least 1 index||16 (24.2%)||0|
Category: Respiratory Symptoms
Tags: bronchodilator, bronchodilator response, hyperreactivity, hyperresponsiveness, infants bronchiolitis, lung function